Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.

Coates, Laura C; Mease, Philip J; Gladman, Dafna D; Navarra, Sandra; Bao, Weibin; Gaillez, Corine

Coates, Laura C; Mease, Philip J; Gladman, Dafna D; Navarra, Sandra; Bao, Weibin; Gaillez, Corine.

Afiliação

Coates LC; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK laura.coates@ndorms.ox.ac.uk.
Mease PJ; Department of Rheumatology, Swedish Medical Centre/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.
Gladman DD; Department of Rheumatology, Toronto Western Hospital, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, Toronto, Ontario, Canada.
Navarra S; Department of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines.
Bao W; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Gaillez C; Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland.

RMD Open ; 9(2)2023 04.

Article em En | MEDLINE | ID: mdl-37094983

Assuntos

Artrite Psoriásica; Humanos; Artrite Psoriásica/tratamento farmacológico; Qualidade de Vida; Anticorpos Monoclonais Humanizados/uso terapêutico; Dor

Palavras-chave

Arthritis, Psoriatic; Biological Therapy; Patient Reported Outcome Measures

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Psoriásica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: RMD Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google